Checkmate Pharmaceuticals Current Assets

Checkmate Pharmaceuticals posts a current assets of $62M as of March 2022. That compares with $94M in the prior-year period — down 34.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Checkmate Pharmaceuticals's current assets was $94M. The latest reading is $62M — a 34.0% year-over-year decrease (period ending March 2022). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Checkmate Pharmaceuticals's financial statement story. At $62M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CMPI's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Checkmate Pharmaceuticals's other metric pages and overview cover the third.

Judging Checkmate Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current assets easier to interpret. Start with $62M here, then scan peer and history charts to see if the gap is persistent.